To exclude that the observed effects of SP8 are only restricted to Hep3B cells, we additionally performed transient gain- and loss-of-function studies in the five liver cancer cell lines HepG2, Hep3B, HUH7, HUH6, and HepT1, which show either high (HepT1 and HUH6) or low levels (HepG2, Hep3B, HUH7) of endogenous SP8 expression (Supporting Experimental Procedures Figure S3). This evidence concerns the gene SP8 and liver cancer.